Alnylam Pharma (0HD2) Drug Pipeline
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alnylam Pharmaceuticals (GB:0HD2) have in its pipeline
Alnylam Pharma GB:0HD2 is currently developing the following drugs: Aln-App, Mivelsiran, Aln-6222, Aln-6400, Zilebesiran, Aln-Agt01 Rvr, Aln-4324, Tirzepatide, Aln-2232, Aln-4915, Aln-4285, Vutrisiran, Nucresiran, Aln-5288, Zilebesiran, Sterile Normal Saline, Nucresiran, Vutrisiran, Aln-Agt01 Rvr, Pembrolizumab, Aln-Bcat, Aln-Htt02, Aln-App, Aln-Khk, Aln-Ttrsc04, Aln-Xdh, Lumasiran, Amlodipine, Indapamide, Olmesartan, Zilebesiran, Aln-Agt01, Pozelimab, Cemdisiran, Aln-Hsd, Vir-2218, Vir-2218, Pegylated Interferon-Alfa 2A, Sterile Normal Saline, Vutrisiran, Patisiran, Irbesartan, Aln-Agt01, Cemdisiran, Aln-Aat02. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
